Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: wheel (17), pedals (5)

Cyclophosphamide and Etoposide

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CYCLOPHOSPHAMIDE and ETOPOSIDE Regimen SCLC - Cyclophosphamide and Etoposide Indication First or second line therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/CyclophosphamideandEtoposide.pdf

Cyclophosphamide, Doxorubicin, Vincristine

Description: Regimen Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CYCLOPHOSPHAMIDE-DOXORUBICIN-VINCRISTINE SCLC – Cyclophosphamide-Doxorubicin-Vincristine Indication Second line treatment of SCLC
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/CyclophosphamideDoxorubicinVincristine.pdf

Carboplatin AUC6

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC6) 6 CYCLES Regimen  Breast Cancer – Carboplatin (AUC6) 6 cycles Indication  Treatment of metastatic breast cancer
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-AUC6.pdf

Carboplatin

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) CARBOPLATIN (AUC6) 6 CYCLES Regimen  SCLC - Carboplatin (AUC6) 6 Cycles Indication  Second line treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Carboplatin.pdf

Papers Council of Governors 20 July 2022

Description: Agenda attachments 1 CoG Agenda - 20.07.2022.docx Date Time Location Chair Agenda Council of Governors 20/07/2022 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-20-July-2022.pdf

CCP-UK Patient Data Notification v0.2 05MAY2022

Description: _______________________________________________ CCP-UK Patient Data Notification _______________________________________________ The purpose of this document is to inform our participants about how their data
Url: /Media/Southampton-Clinical-Research/Downloads/CCP-UK-Patient-Data-Notification-v0.2-05MAY2022.pdf

Rituximab SC (8 weekly) Ver 1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent therapy in previously untreated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (8 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

CVP-Cyclophosphamide-Prednisolone-Vincristine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-VINCRISTINE (CVP) Regimen Lymphoma – CVP-Cyclophosphamide-Prednisolone-Vincristine Indication Non Hodgkin’s Lymphoma Toxicity Drug Adverse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CVP-Cyclophosphamide-Prednisolone-Vincristine-Ver-1.2.pdf

281 to 290 of 1000

Previous … 27 28 29 30 31 … Next